SCHEMBL5259732

SCHEMBL5259732

CNc1nccc(Nc2ccc(-c3nc4ccccc4s3)cc2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 1.00
FLT4 P35916 6/20 1.00
INSR P06213 5/20 1.00
AURKA O14965 9/20 0.83
AURKB Q96GD4 6/20 0.66
APP P05067 2/20 0.64
MEN1 O00255 1/20 0.64
GLA P06280 1/20 0.64
GAA P10253 1/20 0.64
KMT2A Q03164 1/20 0.64
EGFR P00533 6/20 0.56
ERBB2 P04626 2/20 0.56
IGF1R P08069 3/20 0.53
SRC P12931 3/20 0.53
TEK Q02763 2/20 0.52
EPHB4 P54760 1/20 0.52
TP53 P04637 2/20 0.51
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5259629 0.91 AURKA (1.00) KDRFLT4INSRAURKAAURKB
SCHEMBL5257695 0.87 KDR (0.78) KDRFLT4INSRAURKAAURKB
SCHEMBL5260799 0.81 FLT4 (1.00) KDRFLT4INSRAURKAAURKB
SCHEMBL5260098 0.80 AURKA (1.00) KDRFLT4INSRAURKAAURKB
SCHEMBL29523038 0.79 APP (1.00) KDRFLT4INSRAURKAAPP
SCHEMBL493341 0.79 APP (1.00) KDRFLT4INSRAURKAAPP
SCHEMBL2628266 0.79 APP (1.00) KDRFLT4INSRAURKAAPP
SCHEMBL24155562 0.79 APP (0.76) KDRFLT4INSRAURKAAURKB
SCHEMBL5258236 0.78 AURKA (0.78) KDRFLT4INSRAURKAAURKB
SCHEMBL14195557 0.76 APP (0.71) KDRFLT4INSRAURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 KDR 429/4885FLT4 1772/4885INSR 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.